15th Annual Meeting of the Society of Urologic Oncology – Dec 4

15th Annual Meeting of the Society of Urologic Oncology

Dec 3-5, 2014

Bethesda, Maryland

Prostate Cancer Session I

Dec. 4

BIOLOGY OF PROSTATE CANCER

Moderator: Laurence H. Klotz, MD, FRCS(C)

Dr. Klotz is an affiliate scientist at Sunybrook Health Services Centre in Toronto, Canada. He received his medical degree from the University of Toronto, completed a residency in the Gallie program in surgery at the University of Toronto, and was a special fellow in uro-oncology and tumor biology at Memorial Sloan Kettering Cancer Center in New York City.

Dr. Klotz’s laboratory has been studying the effect of selected micronutrients—particularly vitamin E, selenium and lycopene—in the prevention of prostate cancer. In a preclinical model, which spontaneously develops prostate cancer by eight months of age, his team has demonstrated that supplementing food with these micronutrients results in a dramatic and profound reduction in the development of these cancers. The major thrust of Dr. Klotz’s research is to analyze the mechanisms by which these cancers are prevented.

Histology vs Genomics: Does Gleason 3 Have the Hallmarks of Cancer?

Yes: Jonathan I. Epstein, MD

Dr. Epstein is the Reinhard Professor of Urologic Pathology at Johns Hopkins Medical Institutions and the director of surgical pathology at Johns Hopkins Hospital. He received his medical education at Boston University and completed residencies at John Hopkins Hospital and Memorial Sloan Kettering Cancer Center in New York City.

He has published numerous articles on the biology of prostate cancer. He is a member of several professional organizations including the American Urological Association, the Maryland Pathology Society, and the International Society of Urologic Pathology and the recipient of many awards including the Johns Hopkins Urology Faculty Teaching Awards, The Johns Hopkins Pathology Faculty Teaching Award, and the International Society of Urological Pathology Grawitz medal.

No: Mark A. Rubin, MD

Dr. Rubin is professor of pathology and laboratory medicine and the Homer T. Hirst III Professor of Oncology in Pathology at Weill Cornell Medical College. He received his medical degree from the Mount Sinai School of Medicine

The focus of Dr. Rubin’s laboratory based research during the past decade has been the development of molecular biomarkers capable of distinguishing indolent from aggressive prostate cancer. He holds United States and international patents for molecular biomarkers. He has been the principal investigator of three NIH sponsored RO1 grant awards, a U01 grant, a Prostate SPORE project and a Department of Defense Idea Award, all in the area of prostate cancer progression. His research relies on close collaboration with scientists and physician scientists in urology, medical oncology, and molecular biology.

Should MR be the Standard of Care before Biopsy?

Yes:  Samir S. Taneja, MD

Dr. Taneja is the James M. Neissa and Janet Riha Neissa Associate Professor of Urologic Oncology, director of the Division of Urologic Oncology in the Department of Urology at the NYU Langone Medical Center, program leader of the Genitourinary Oncology Program of the NYU Cancer Institute, and, currently, chief of the Urology Section at the Veterans Administration New York Harbor Healthcare System Manhattan Campus (Manhattan VA Medical Center). Dr. Taneja received his undergraduate and medical education at Northwestern University Medical School.

Dr Taneja is a leader in the treatment and research of urologic cancers. He has served as Oncology Task Force member and chair for the American Board of Urology Exam Committee, program chair and Executive Committee member for the Society of Urologic Oncology, and, most recently, Secretary General of the Urologic Research Society. He has authored more than 110 articles, 20 book chapters, and 5 textbooks on urologic cancer and urologic surgery.

No: Andrew J. Stephenson, MD

Dr. Stephenson is the director for the Center of Urologic Oncology at Cleveland Clinic’s Glickman Urological and Kidney Institute and a staff member of the Taussig Cancer Institute. His clinical and research focus is the treatment of patients with cancers of prostate, bladder, testis, and kidney. He has published more than 100 articles in peer-reviewed journals on issues related to prostate, bladder, kidney and testis cancer, many of which have received international mainstream media attention.

Imaging for Biochemical Recurrences

Peter L. Choyke, MD, FACR

Dr. Choyke is program director of the Molecular Imaging Program and head of the Imaging Section at the Center for Cancer Research of the National Cancer Institute. He obtained his medical degree from Jefferson Medical College and completed his residency in diagnostic radiology at Yale-New Haven Hospital.

His research interests include the translation of molecular imaging methods, such as MRI, optical and radionuclide/PET into the clinic. His research includes novel methods of detecting ovarian cancer, prostate cancer, angiogenesis, lymphangiogenesis, cancer cell receptor imaging and treatment, cell tracking, and exploration of unique animal models of cancer.

STATE-OF-THE-ART LECTURE I

Targeting Hormone-DNA Repair Crosstalk in Prostate Cancer: Implications for Disease Progression and Therapeutic Intervention

Karen E. Knudsen, PhD

Dr. Knudsen is professor of cancer biology, urology and radiation oncology at Thomas Jefferson University and NCI-designated Kimmel Cancer Center in Philadelphia. She earned her PhD, focused on cell cycle checkpoint control, from the University of California at San Diego.

Her research interests are focused on understanding the mechanisms by which hormone receptor and cell cycle deregulation lead to prostate cancer progression and therapeutic bypass. The overall goal of Dr. Knudsen’s laboratory is to utilize this information for successful development of precision medicine, so as to improve therapeutic outcome and patient care through rational therapy delivery. Her studies identifying tumor suppressor and hormone receptor alterations have uncovered new targets for treating advanced disease, and led to development of biomarker-driven clinical trials.